ACL australian clinical labs limited

News: ACL Australian Clinical Labs Expects COVID Testing To Continue To Moderate In H2

  1. 193,698 Posts.
    lightbulb Created with Sketch. 2825

    Feb 24 (Reuters) - Australian Clinical Labs Ltd (ACL) :

    • DOES NOT PLAN TO PROVIDE GUIDANCE FOR FY22 AT THIS TIME
    • DURING 2H FY22, ACL ANTICIPATES TESTING FOR COVID TO CONTINUE TO MODERATE
    • FINAL DIVIDEND WILL BE CONSIDERED AT FULL YEAR, BASED ON FINANCIAL PERFORMANCE, CAPITAL NEEDS AND CORPORATE ACTIVITY
    • IN H2, ANTICIPATES REBOUND IN NON-COVID TESTING TO CONTINUE AS RESTRICTIONS ON ESSENTIAL SURGERIES EASE
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$2.62
Change
0.020(0.77%)
Mkt cap ! $514.5M
Open High Low Value Volume
$2.62 $2.62 $2.58 $917.7K 352.9K

Buyers (Bids)

No. Vol. Price($)
1 200 $2.58
 

Sellers (Offers)

Price($) Vol. No.
$2.62 293 1
View Market Depth
Last trade - 16.10pm 08/09/2025 (20 minute delay) ?
ACL (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.